Skip to main
SRDX
SRDX logo

Surmodics (SRDX) Stock Forecast & Price Target

Surmodics (SRDX) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surmodics Inc. is poised for substantial revenue growth due to its strategic investment in a whole-products solutions approach, which has led to the establishment of a direct sales force for its Pounce thrombectomy and Sublime radial access products. Despite increased operating expenses associated with these initiatives, the company's focus on enhancing its Medical Device segment, which includes advanced performance coating technologies and innovative medical devices, demonstrates its commitment to strengthening its market position. Overall, this proactive investment strategy, particularly within the domestic market, positions Surmodics favorably for future financial performance.

Bears say

Surmodics Inc. is facing significant challenges, primarily due to declining sales of its SurVeil drug-coated balloon, which has been compounded by reduced license fee revenue and lower sales to its distribution partner, Abbott. The company anticipates a larger-than-expected decrease in SurVeil sales for fiscal year 2025, which raises concerns about overall revenue growth. Additionally, the impact of these headwinds, including diminished coating royalty and license fee catch-up payments, is likely to further strain the financial performance of its Medical Device segment, which is crucial for the company’s revenue generation.

Surmodics (SRDX) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surmodics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surmodics (SRDX) Forecast

Analysts have given Surmodics (SRDX) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Surmodics (SRDX) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surmodics (SRDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.